Arvest Bank Trust Division Sells 1,608 Shares of Gilead Sciences, Inc. (GILD)

Share on StockTwits

Arvest Bank Trust Division trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 222,238 shares of the biopharmaceutical company’s stock after selling 1,608 shares during the period. Arvest Bank Trust Division’s holdings in Gilead Sciences were worth $14,447,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Athena Capital Advisors LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $27,000. Capital Financial Planning LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $27,000. Advisors Preferred LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $31,000. Legacy Financial Advisors Inc. lifted its holdings in shares of Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 383 shares in the last quarter. Finally, Claybrook Capital LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at $32,000. 80.19% of the stock is currently owned by institutional investors.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $67.23, for a total value of $181,521.00. Following the completion of the transaction, the director now directly owns 57,560 shares in the company, valued at approximately $3,869,758.80. The disclosure for this sale can be found here. In the last three months, insiders sold 39,402 shares of company stock worth $2,613,954. 0.20% of the stock is owned by corporate insiders.

GILD stock opened at $65.43 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38. The stock has a market capitalization of $84.58 billion, a price-to-earnings ratio of 10.64, a PEG ratio of 4.17 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the prior year, the company posted $1.78 EPS. The firm’s revenue was down 2.6% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.63 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $2.52 dividend on an annualized basis and a yield of 3.85%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

A number of research analysts have recently issued reports on the company. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 23rd. Mizuho reaffirmed a “buy” rating and set a $88.00 price target on shares of Gilead Sciences in a report on Tuesday, February 26th. Citigroup reaffirmed a “buy” rating and set a $100.00 price target on shares of Gilead Sciences in a report on Tuesday, February 5th. Maxim Group reaffirmed a “buy” rating and set a $84.00 price target on shares of Gilead Sciences in a report on Friday, March 29th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Gilead Sciences in a report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average target price of $82.00.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://macondaily.com/2019/04/16/arvest-bank-trust-division-sells-1608-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: How to find the components of the quick ratio

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.